TARS
HEALTHCARETarsus Pharmaceuticals Inc
$64.76-0.28 (-0.43%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TARS Today?
No stock-specific AI insight has been generated for TARS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$38.51$85.25
$64.76
Fundamentals
Market Cap$2.8B
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume940K
Avg Volume (10D)—
Shares Outstanding43.0M
TARS News
22 articles- Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish NarrativesSimply Wall Street·May 8, 2026
- Tarsus to Participate in Upcoming Investor ConferencesYahoo Finance·May 7, 2026
- Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dipsInvesting.com Australia·May 7, 2026
- Tarsus Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Tarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsYahoo Finance·May 6, 2026
- Amgen (AMGN) Q1 Earnings and Revenues Beat EstimatesYahoo Finance·Apr 30, 2026
- Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026Yahoo Finance·Apr 29, 2026
- Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing LossesYahoo Finance·Apr 3, 2026
- How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) InvestorsYahoo Finance·Apr 3, 2026
- Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme DiseaseYahoo Finance·Mar 31, 2026
- Tarsus Pharmaceuticals Stock Earns Upgrade To RS RatingYahoo Finance·Mar 26, 2026
- Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked TradeThe Motley Fool·Mar 24, 2026
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusYahoo Finance·Mar 23, 2026
- Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?Motley Fool·Mar 22, 2026
- Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share PerformanceYahoo Finance·Mar 9, 2026
- Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform RatingYahoo Finance·Mar 6, 2026
- Maker Of Eye Drops Has Sights On Buy PointYahoo Finance·Mar 2, 2026
- These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.Yahoo Finance·Feb 27, 2026
- Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines?Yahoo Finance·Feb 26, 2026
- Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Feb 24, 2026
All 22 articles loaded
Price Data
Open$65.50
Previous Close$65.04
Day High$66.02
Day Low$63.70
52 Week High$85.25
52 Week Low$38.51
52-Week Range
$38.51$85.25
$64.76
Fundamentals
Market Cap$2.8B
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume940K
Avg Volume (10D)—
Shares Outstanding43.0M
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—